Denali Therapeutics (NASDAQ:DNLI) Given New $34.00 Price Target at Robert W. Baird

Key Points

• Robert W. Baird raised its price target on Denali Therapeutics to $34 and kept an "outperform" rating, implying about a 75% upside, while other firms (Goldman to $40, Stifel to $41) have also lifted targets and the consensus is a "Moderate Buy" with a $35 target.
• Shares trade around $19.38 with a market cap of about $3.07 billion; the company remains unprofitable (negative P/E) but posted a slight quarterly EPS beat (‑$0.73 vs. ‑$0.75) and analysts forecast a full‑year EPS of about -2.71.
• Denali is a clinical‑stage biopharma focused on neurodegenerative diseases using a Blood–Brain Barrier Transport Vehicle platform, with lead programs including an LRRK2 inhibitor for Parkinson's and an anti‑TREM2 antibody for Alzheimer's.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) had its price target raised by research analysts at Robert W. Baird from $32.00 to $34.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Robert W. Baird's price target would indicate a potential upside of 75.44% from the stock's previous close.

A number of other brokerages have also commented on DNLI. The Goldman Sachs Group lifted their price target on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, March 26th. Wolfe Research assumed coverage on shares of Denali Therapeutics in a report on Monday, February 23rd. They issued a "peer perform" rating on the stock. Stifel Nicolaus boosted their target price on shares of Denali Therapeutics from $34.00 to $41.00 and gave the company a "buy" rating in a report on Thursday, March 26th. UBS Group assumed coverage on shares of Denali Therapeutics in a report on Wednesday, January 7th. They issued a "buy" rating on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Denali Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $35.00.

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI opened at $19.38 on Tuesday. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $23.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The stock has a market capitalization of $3.07 billion, a price-to-earnings ratio of -6.53 and a beta of 1.10. The company's 50 day simple moving average is $20.46 and its 200 day simple moving average is $18.12.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.02. During the same quarter last year, the business posted ($0.67) earnings per share. As a group, research analysts predict that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNLI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Denali Therapeutics by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company's stock valued at $1,210,000 after purchasing an additional 3,432 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Denali Therapeutics by 58.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company's stock worth $22,732,000 after acquiring an additional 614,555 shares in the last quarter. Empowered Funds LLC increased its position in shares of Denali Therapeutics by 11.0% during the first quarter. Empowered Funds LLC now owns 20,639 shares of the company's stock worth $281,000 after acquiring an additional 2,052 shares in the last quarter. Woodline Partners LP increased its position in shares of Denali Therapeutics by 13.5% during the first quarter. Woodline Partners LP now owns 113,517 shares of the company's stock worth $1,543,000 after acquiring an additional 13,517 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Denali Therapeutics by 1.7% during the second quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company's stock worth $2,681,000 after acquiring an additional 3,210 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.